Anastasia Sevriukova landed her dream job and got engaged. Then, she learned she had stage 4 colon cancer.

A breast cancer diagnosis reinforced the value of expert care and personal connection throughout Dr. Lorrie Basnight’s treatment at ECU Health.

Learn how SBRT can shorten cancer radiation treatment from weeks to just one to five days, and which cancers may be eligible for this approach.

In the third quarter of 2026, the FDA issued approvals for new treatment options for cancers of the breast, lung, pancreas, and more.

Cancer immunotherapy can lose its punch when tumor-fighting T cells become exhausted, but researchers may have found a way to keep them going longer. Scientists at Memorial Sloan Kettering Cancer Cent...

Breast oncologist Elisa Krill Jackson, M.D., explains advances in targeted treatment, tumor genomics and clinical trials for breast cancer.

A short course of ultra-low-dose radiation therapy relieved painful bone lesions from multiple myeloma for most patients in a multi-institutional Phase II clinical trial. The findings suggest that a l...

Ivonescimab outperformed Keytruda, a new myeloma drug lowered progression risk by 60% and more: the biggest phase 3 cancer results of September 2026.

September brought new options for breast, lung, kidney, bile duct, skin and neuroendocrine cancers, plus a brain tumor scan and easier lung cancer treatment.

Diagnosed with a type of acute leukemia last year, Leila Macy turned to Baptist Health Herbert Wertheim Cancer Institute for treatment. She says her recovery is “excellent” as she resumes her busy lif...

Men with high-risk prostate cancer have a higher likelihood of having residual disease following prostatectomy and may require radiation therapy after surgery, particularly when PSA levels begin to ri...

The FDA has approved new first-line zanidatamab-based treatment options for certain people with HER2-positive advanced stomach, gastroesophageal junction, and esophageal cancers. In a major clinical t...

/PRNewswire/ -- Leo Cancer Care has announced plans to further invest in the treatment experience for children undergoing radiation therapy. Following the...

The Accela radiotherapy solution is engineered around NeoArc dynamic modulated arc therapy (DMAT),  a breakthrough technique combining speed and precision. NeoArc makes single breath-hold stereotactic...

UAB clinical trial explores new approach to treat ovarian cancer

On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal gr...

After a gynecologic cancer diagnosis and limited access to specialty cancer care, Nan Magdits traveled 1,700 miles for lifesaving treatment at City of Hope. Learn more.

Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.

This disease is highly treatable if caught early—but in its earliest stages, prostate cancer often has no symptoms, allowing it to develop without detection. Learn more about this common cancer and ho...

TAMP delivers chemotherapy directly to hard-to-reach pancreatic tumors. Learn how this new pancreatic cancer treatment works at Hackensack Meridian Health.

One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see. New research from Dana-Farber Cancer Institute scient...

Jeff Sharman, MD, discusses bispecific antibodies, CAR T-cell therapy, and targeted agents reshaping non-Hodgkin lymphoma treatment.

Daraxonrasib plus gemcitabine and nab-paclitaxel received FDA breakthrough therapy designation for treatment-naive metastatic pancreatic adenocarcinoma.

The University of Michigan has launched a first-of-its-kind research center that will use ultrasound to treat cancer, a technology invented by U-M researchers in 2002.

The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.

Dr. Roy Herbst introduces the program and presents clinical scenario 1: a 61-year-old woman with a 4-week history of dry cough, CT-confirmed 3.2 cm spiculated right lower lobe nodule, no mediastinal l...

Marsoni et al. evaluated the feasibility of a dynamic circulating tumor DNA-guided adjuvant and postadjuvant treatment strategy in patients with resected microsatellite-stable, high-risk stage II or I...

Treatment yields positive results despite late diagnosis and cardiac involvement

Prostate cancer treatment has advanced rapidly in five years. Explore key FDA approvals, improved treatments and what these changes mean for patients.

Patients with advanced abdominal cancers who are not candidates for tumor-removing surgery now have access to a treatment that may help control disease within the abdomen, reduce symptoms, preserve qu...

Johnson said he hopes the cell therapy will eventually produce “robust” and “long-lived” effects that extend patients’ life expectancies. 

Amgen's targeted immunotherapy, Imdelltra, combined with AstraZeneca's cancer drug ​Imfinzi, significantly improved overall survival in patients with extensive-stage small-cell ‌lung cancer in a late-...

The FDA approved Etcamah, Camizestrant, for HR-positive/HER2-negative advanced breast cancer with an ESR1 mutation. Here’s what to know.

T-cell receptor, or TCR, therapy is a cancer treatment that genetically reprograms immune cells, called T cells, to hunt down cancer with precision. It's similar to another treatment, CAR T-cell thera...

Rene Haas also claims artificial intelligence could pave way for widespread use of humanoid robots within five years

Dr. Andrew Ip answers common lymphoma questions, from diagnosis and treatment options to CAR T-cell therapy, side effects and hope for patients.

The FDA has granted accelerated approval to Etcamah (camizestrant), marking the first FDA approval of a cancer therapy guided by the detection of a resistance mutation in circulating tumor DNA before ...

The medicine doubled survival time for patients in a Phase 3 clinical trial.

The U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innovation and getting new t...

The FDA approved six cancer drugs in August 2026, including a landmark pancreatic cancer pill. Here's what each approval means for patients and side effects.

Results bolster hopes that the drug daraxonrasib could prove effective against a variety of tumours.

UCSF researchers helped test the first personalized mRNA cancer vaccine shown to prevent melanoma from returning or spreading, marking a breakthrough in cancer treatment.

Thang et al. review the barriers to clinical trial participation in pancreatic cancer across the patient pathway, from referral to enrolment. They identify coordinated improvements in referral, molecu...

The Penn spinout launched a year ago with CAR-T pioneer Carl June as a scientific co-founder and $216 million in funding from private investors. It dosed its first patient in a clinical trial.

FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate cancer, as phase 1/2 trial readies 2026 enrollment.

CAR T-cell therapy dramatically reduced disease activity in six people with severe rheumatoid arthritis that had resisted other treatments, with three achieving medication-free remission. The treatmen...

A five-year funding award led by Mohamed Sorror, MD, MS, from the Patient-Centered Outcomes Research Institute (PCORI) will support three national randomized trials.